Nature1 个月
Epidermal growth factor receptor mutations in lung cancer
The Ras–MAPK (mitogen-activated protein kinase) pathway is another important cell-proliferation pathway downstream of EGFR that is frequently activated in cancer. Although mutations in Ras ...
腾讯网1 个月
聚焦 EGFR 突变 III 期不可切除 NSCLC，解读靶向巩固治疗新进展
2024 年，非小细胞肺癌（NSCLC）治疗领域迎来了累累硕果。尤其是针对 EGFR 突变 III 期不可切除 NSCLC 的靶向巩固治疗研究，取得了令人振奋的突破性 ...
腾讯网21 天
恒瑞医药：皮下注射靶向EGFR/c-Met双抗在中国获批开展临床试验
今日，恒瑞医药宣布，公司收到国家药品监督管理局（以下简称 “国家药监局”）核准签发关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，将 ...
Cure Today5 天
New Trial to Test Light Therapy Plus Keytruda in Head and Neck Cancer
A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...
Healio28 天
National Kidney Foundation consensus: Race-free eGFR may optimize decision-making
It shows how adjusting eGFR results for body surface may improve decision results. The National Kidney Foundation published a consensus document that advocates transition to race-free eGFR ...
新浪网20 天
信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新（利厄 ...
利厄替尼治疗EGFR T790M突变阳性NSCLC关键IIB期临床研究中，共计入组了 301 例经既往EGFR-TKI治疗后进展的EGFR T790M突变阳性或原发性EGFR T790M突变阳性局部 ...
c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies ...
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...
Squamous Cell Carcinoma Pipeline Insights Report | DelveInsight
DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor ...